Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for prevention of contrast nephropathy in PCI patients with renal insufficiency
ChiCTR2200064264Phase 4Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nicorandil in contrast-induced nephropathy (CIN), coronary arteriosclerosis and Renal Insufficiency (RI) (3 arms), sponsored by Dongguan People's Hospital. Primary endpoint: Incidence of contrast nephropathy. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
contrast-induced nephropathy (CIN)coronary arteriosclerosisRenal Insufficiency (RI)
Beyond the preview
Go deeper on ChiCTR2200064264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064264.